lymphoma
Genmab to submit FDA application for lymphoma therapy
May 2, 2025Research and Development AbbVie, Biologics License Application, FDA, Genmab, Oncology, epcoritamab, lymphoma, therapeutics
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) …
National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
August 6, 2024Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE)Â for treatment …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
May 3, 2024Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial
March 1, 2024Medical Communications Oncology, Viracta Therapeutics, lymphoma
Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …
NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL
February 1, 2024Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
December 11, 2023Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …
NMPA approves CStone’s Cejemly for lymphoma treatment
October 31, 2023Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma
CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …
Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting
June 5, 2023Research and Development Allogene, LBCL, Oncology, lymphoma, oncology
Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …
EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma
October 20, 2020Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma
Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …
NICE rejects mycosis fungoides-type cutaneous T-cell lymphoma therapy over data concerns
August 5, 2020Research and Development, Sales and Marketing Ledaga, NICE, lymphoma
NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell …
MSD’s Phase 3 study of lymphoma treatment meets primary endpoints
March 3, 2020Manufacturing and Production B-cell lymphoma, classical Hodgkin Lymphoma, lymphoma
MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …
EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma
January 21, 2020Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma
The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.
Takeda commits to advancing treatments for rare bleeding disorders and cancer
December 10, 2019Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology
Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …
Latest content
FibroFind appoints Lee Borthwick as CEO
